BiotechTube
All Reports
🎯

Oncology

Competitive landscape report · 209 products · 45 companies

Executive Summary

The oncology landscape features 209 products in active development across 45 companies. The space remains highly competitive with significant activity across all clinical stages.

23 products are currently in Phase 3 trials, 83 in Phase 2, and 69 in Phase 1. Leading companies by pipeline count include Eli Lilly, Zentalis Pharmaceuticals, eFFECTOR Therapeutics.

1 products have received regulatory approval. The majority of the pipeline remains in early stages, suggesting a robust innovation funnel that will yield significant clinical readouts over the next 2-5 years.

Top Products by Hype Score

1
arzoxifeneBreast Cancer
Eli Lilly
Approved
85
2
Pemetrexed + CarboplatinNon Small Cell Lung Carcinoma
Eli Lilly
Phase 3
77
3
Pemetrexed + Cisplatin + Placebo + PemetrexedNon-Small Cell Lung Cancer
Eli Lilly
Phase 3
77
4
Tasisulam-sodium + PaclitaxelMelanoma
Eli Lilly
Phase 3
77
5
Pirtobrutinib + Venetoclax + RituximabChronic Lymphocytic Leukemia
Eli Lilly
Phase 3
77
6
pemetrexed + docetaxelNon-Small Cell Lung Cancer
Eli Lilly
Phase 3
77
7
PemCarbo + Pem onlyNon-small Cell Lung Cancer
Eli Lilly
Phase 3
77
8
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibMetastatic Non-Small Cell Lung Cancer
Eli Lilly
Phase 3
77
9
Ramucirumab + Paclitaxel + PlaceboGastroesophageal Junction Adenocarcinoma
Eli Lilly
Phase 3
77
10
Ramucirumab + PlaceboHepatocellular Carcinoma
Eli Lilly
Phase 3
77

Top Companies by Pipeline Count

1Eli Lilly91 products2Zentalis Pharmaceuticals12 products3eFFECTOR Therapeutics12 products4Celltrion12 products5Perspective Therapeutics6 products6BioAtla6 products7Affimed4 products8CSPC Pharmaceutical Group Limited4 products9Precigen4 products10Navidea Biopharmaceuticals3 products

Phase Distribution

Pre-clinical
5
Phase 1
69
Phase 1/2
27
Phase 2
83
Phase 2/3
1
Phase 3
23
Approved
1

Key Trends & Analysis

Pro

Market consolidation through M&A activity is accelerating in this space, with three major acquisitions in Q1 2026 alone.

Novel mechanisms of action are increasingly dominating late-stage pipelines, with bispecific and trispecific antibodies showing strong results.

Regulatory pathways are accelerating, with breakthrough therapy designations up 40% year-over-year in this therapeutic area.

Upgrade to Pro for full analysis

View plans
Back to all reports